Nimodipine
Nimodipine, Nymalize (nimodipine) is a small molecule pharmaceutical. Nimodipine was first approved as Nimotop on 1988-12-28. It is used to treat subarachnoid hemorrhage in the USA. The pharmaceutical is active against mineralocorticoid receptor. In addition, it is known to target voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1D, cystic fibrosis transmembrane conductance regulator, voltage-dependent L-type calcium channel subunit alpha-1S, and voltage-dependent L-type calcium channel subunit alpha-1C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nimodipine, Nymalize (discontinued: Nimodipine, Nimotop, Nymalize)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nimodipine | ANDA | 2024-08-16 |
| nymalize | New Drug Application | 2024-08-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| subarachnoid hemorrhage | EFO_0000713 | D013345 | I60 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 3 | 4 | 2 | 1 | 6 | 15 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 3 | 4 | 2 | 1 | 6 | 15 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | 1 | 2 | 4 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | 1 | 1 | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | 1 | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 1 | 2 |
| Depression | D003863 | — | F33.9 | — | 1 | — | 1 | — | 2 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | — | — | 1 | 1 | 2 |
| Syndrome | D013577 | — | — | — | — | — | 1 | 1 | 2 |
| Cerebral infarction | D002544 | — | I63 | — | — | — | 1 | 1 | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | 1 | 2 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | — | — | 2 | 3 |
| Infertility | D007246 | HP_0000789 | — | — | 1 | — | — | 1 | 2 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 1 | — | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
| Delirium | D003693 | — | R41.0 | — | 1 | — | — | — | 1 |
| Electroconvulsive therapy | D004565 | — | — | — | 1 | — | — | — | 1 |
| Acoustic neuroma | D009464 | HP_0009588 | — | — | 1 | — | — | — | 1 |
| Neurilemmoma | D009442 | EFO_0000693 | — | — | 1 | — | — | — | 1 |
| Aneurysm | D000783 | HP_0002617 | I72.9 | 1 | 1 | — | — | — | 1 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | 1 | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | 1 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | — | — | — | 1 | 2 |
| Brain injuries | D001930 | — | S06.9 | 1 | — | — | — | 1 | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | — | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | — | — | 1 |
| Psychotic affective disorders | D000341 | — | F39 | 1 | — | — | — | — | 1 |
| Neurologic manifestations | D009461 | — | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | — | — | — | 2 | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 2 | 2 |
| Bronchopulmonary dysplasia | D001997 | — | P27.8 | — | — | — | — | 2 | 2 |
| Lung injury | D055370 | — | S27.30 | — | — | — | — | 2 | 2 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 2 | 2 |
| Ventilator-induced lung injury | D055397 | — | — | — | — | — | — | 2 | 2 |
| Bundle-branch block | D002037 | HP_0011713 | I44.7 | — | — | — | — | 2 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Anovulation | D000858 | — | — | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nimodipine |
| INN | nimodipine |
| Description | Nimodipine is a dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm. It has a role as an antihypertensive agent, a calcium channel blocker, a vasodilator agent and a cardiovascular drug. It is a dihydropyridine, a C-nitro compound, a diester, a member of dicarboxylic acids and O-substituted derivatives, a 2-methoxyethyl ester and an isopropyl ester. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1 |
Identifiers
| PDB | — |
| CAS-ID | 66085-59-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1428 |
| ChEBI ID | 7575 |
| PubChem CID | 4497 |
| DrugBank | DB00393 |
| UNII ID | 57WA9QZ5WH (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Alternate
CACNA1D
CACNA1D
CACNA1C
CACNA1C
Organism
Homo sapiens
Gene name
CACNA1D
Gene synonyms
CACH3, CACN4, CACNL1A2, CCHL1A2
NCBI Gene ID
Protein name
voltage-dependent L-type calcium channel subunit alpha-1D
Protein synonyms
calcium channel, L type, alpha-1 polypeptide, Calcium channel, L type, alpha-1 polypeptide, isoform 2, calcium channel, neuroendocrine/brain-type, alpha 1 subunit, calcium channel, voltage-dependent, L type, alpha 1D subunit, voltage-gated calcium channel alpha 1 subunit, voltage-gated calcium channel alpha subunit Cav1.3, Voltage-gated calcium channel subunit alpha Cav1.3
Uniprot ID
Mouse ortholog
Cacna1d (12289)
voltage-dependent L-type calcium channel subunit alpha-1D (Q99246)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nimodipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,338 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nimodipine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
590 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use